KMKhilola Mirakhmedova

Khilola Mirakhmedova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Khilola Mirakhmedova has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice

    by Oksana M. Drapkina, Vadim I. Mazurov, Martynov I. Martynov, Evgeny L. Nasonov, Sergey A. Saiganov, Aleksander M. Lila, Roman A. Bashkinov, Irina N. Bobkova, Chokan T. Baimukhamedov, Inna Z. Gaydukova, et al.

    Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate. This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.


  • COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

    by Aisulu Karkabayeva, Khilola Mirakhmedova, Shoira Khusinova, Abdimutalib Mamasaidov, Chokan Baimukhamedov

    We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020–2023) and compares the same with the pre-pandemic period (2016–2019). We assume that SARS-CoV-2 triggers ARD. This study concerns the 10 million population of Greece, and this work convincingly confirms our hypothesis. Besides, four large cohort studies have demonstrated an increased incidence of autoimmune diseases after surviving COVID-19. Compared to the prepandemic period, all ARD increased, and RA growth in the index study reached a level of more than 20% during the pandemic. A similar trend was observed in our report covering four Central Asian republics, namely Kazakhstan, Kyrgyzstan, Uzbekistan, and Tajikistan. The alarming growth of ARDs due to the consequences of the pandemic can still be predicted for the coming years. Healthcare professionals worldwide should be aware of this hypothesis to plan their COVID-19, long COVID, and ARD diagnostic and therapeutic strategies. We agree with the authors of the index article that more resources and research studies are warranted to optimize the diagnosis and treatment of ARDs in this challenging time.


  • Open Access

    Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice

    by O. M. Drapkina, V. I. Mazurov, A. I. Martynov, E. L. Nasonov, S. A. Saiganov, A. M. Lila, R. A. Bashkinov, I. N. Bobkova, Ch. T. Baimukhamedov, I. Z. Gaidukova, et al.

    Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике


  • Increasing autoimmune rheumatic diseases as a consequence of the COVID‐19 pandemic: A hypothesis or fact?

    by Chokan Baimukhamedov, Galymzhan Togizbayev, Khilola Mirakhmedova, Abdimutalib Mamasaidov, Surayo Shukurova


  • Long COVID: the time has come for globally acceptable definitions

    by Chokan Baimukhamedov, Khilola Mirakhmedova, Gulzhan Dossybayeva


  • Open Access

    Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?

    by Evgeniya V. Shalaeva, Alisher К. Shadmanov, Feruza L. Azizova, Khilola T. Mirakhmedova, Franz H. Messerli, Oscar H. Franco, Hugo Saner

    Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with increase mortality or a more severe course of COVID-19, and if treatment and control of hypertension mitigates this risk. This is a prospective multi-center observational cohort study with 30-day outcomes of 9,531 consecutive SARS-CoV-2 PCR-positive patients ≥ 18 years old (41.9 ± 9.7 years, 49.2% male), Uzbekistan, June 1-September 30, 2020. Patients were subclassified according to JNC8 criteria into six blood pressure stages. Univariable and multiple logistic regression was conducted to examine how variables predict outcomes. The 30-days all-cause mortality was 1.18% (n = 112) in the whole cohort. After adjusting for age, sex, history of myocardial infarction (MI), type-2 diabetes, and obesity, none of six JNC8 groups showed any significant difference in all-cause mortality. However, age was associated with an increased risk of 30-days all-cause mortality (OR = 1.09, 95%CI [1.07–1.12], p < 0.001), obesity (OR = 7.18, 95% CI [4.18–12.44], p < 0.001), diabetes (OR 4.18, 95% CI [2.58–6.76], p < 0.001), and history of MI (OR = 2.68, 95% CI [1.67–4.31], p < 0.001). In the sensitivity test, being ≥ 65 years old increased mortality 10.56-fold (95% CI [5.89–18.92], p < 0.001). Hospital admission was 12.4% (n = 1,183), ICU admission 1.38% (n = 132). The odds of hospitalization increased having stage-2 untreated hypertension (OR = 4.51, 95%CI [3.21–6.32], p < 0.001), stage-1 untreated hypertension (OR = 1.97, 95%CI [1.52–2.56], p < 0.001), and elevated blood pressure (OR = 1.82, 95% CI [1.42–2.34], p < 0.001). Neither stage-1 nor stage-2 treated hypertension patients were at statistically significant increased risk for hospitalization after adjusting for confounders. Presenting with stage-2 untreated hypertension increased the odds of ICU admission (OR = 3.05, 95 %CI [1.57–5.93], p = 0.001). Lone hypertension did not increase COVID-19 mortality or in treated patients risk of hospitalization.